Tesaro: Difference between revisions
CSV import Tags: mobile edit mobile web edit |
CSV import |
||
| Line 1: | Line 1: | ||
== Tesaro == | |||
[[File:TESARO_logo.png|thumb|right|150px|TESARO logo]] | |||
Tesaro was | '''Tesaro''' was a biopharmaceutical company focused on developing and commercializing cancer therapeutics. Founded in 2010, Tesaro was headquartered in Waltham, Massachusetts, and became known for its work in oncology, particularly in the development of treatments for [[ovarian cancer]] and other solid tumors. | ||
== | === History === | ||
Tesaro was founded by former executives of [[MGI Pharma]], including Lonnie Moulder, Mary Lynne Hedley, and Richard Rodgers. The company quickly gained attention in the biopharmaceutical industry due to its strategic focus on oncology and its ability to secure significant funding for its research and development efforts. | |||
Tesaro | In 2018, Tesaro was acquired by [[GlaxoSmithKline]] (GSK) for approximately $5.1 billion, marking a significant expansion of GSK's oncology portfolio. | ||
== | === Products === | ||
Tesaro developed several key products, with a focus on [[PARP inhibitors]] and other targeted cancer therapies. | |||
==== Niraparib (Zejula) ==== | |||
Niraparib, marketed under the brand name Zejula, is an oral [[PARP inhibitor]] used in the treatment of [[ovarian cancer]]. It was approved by the [[U.S. Food and Drug Administration]] (FDA) in 2017 for use in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy. | |||
== | ==== Rolapitant (Varubi) ==== | ||
Rolapitant, marketed as Varubi, is a [[neurokinin-1 receptor antagonist]] used to prevent [[chemotherapy-induced nausea and vomiting]] (CINV). It was approved by the FDA in 2015 and is used in combination with other antiemetic agents. | |||
=== Research and Development === | |||
Tesaro was involved in several clinical trials aimed at expanding the indications for its existing products and developing new therapies. The company's research focused on leveraging its expertise in [[cancer biology]] and [[drug development]] to create innovative treatments for patients with unmet medical needs. | |||
=== Acquisition by GlaxoSmithKline === | |||
In December 2018, [[GlaxoSmithKline]] announced its acquisition of Tesaro, which was completed in January 2019. This acquisition was part of GSK's strategy to strengthen its oncology pipeline and enhance its capabilities in the development of cancer therapies. | |||
== Related pages == | |||
* [[GlaxoSmithKline]] | * [[GlaxoSmithKline]] | ||
* [[Ovarian cancer]] | |||
* [[PARP inhibitor]] | * [[PARP inhibitor]] | ||
* [[Chemotherapy-induced nausea and vomiting]] | |||
[[Category: | [[Category:Biopharmaceutical companies]] | ||
[[Category:Oncology]] | [[Category:Oncology]] | ||
[[Category:Companies established in 2010]] | |||
[[Category:Companies disestablished in 2019]] | |||
Latest revision as of 03:45, 13 February 2025
Tesaro[edit]
Tesaro was a biopharmaceutical company focused on developing and commercializing cancer therapeutics. Founded in 2010, Tesaro was headquartered in Waltham, Massachusetts, and became known for its work in oncology, particularly in the development of treatments for ovarian cancer and other solid tumors.
History[edit]
Tesaro was founded by former executives of MGI Pharma, including Lonnie Moulder, Mary Lynne Hedley, and Richard Rodgers. The company quickly gained attention in the biopharmaceutical industry due to its strategic focus on oncology and its ability to secure significant funding for its research and development efforts.
In 2018, Tesaro was acquired by GlaxoSmithKline (GSK) for approximately $5.1 billion, marking a significant expansion of GSK's oncology portfolio.
Products[edit]
Tesaro developed several key products, with a focus on PARP inhibitors and other targeted cancer therapies.
Niraparib (Zejula)[edit]
Niraparib, marketed under the brand name Zejula, is an oral PARP inhibitor used in the treatment of ovarian cancer. It was approved by the U.S. Food and Drug Administration (FDA) in 2017 for use in patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.
Rolapitant (Varubi)[edit]
Rolapitant, marketed as Varubi, is a neurokinin-1 receptor antagonist used to prevent chemotherapy-induced nausea and vomiting (CINV). It was approved by the FDA in 2015 and is used in combination with other antiemetic agents.
Research and Development[edit]
Tesaro was involved in several clinical trials aimed at expanding the indications for its existing products and developing new therapies. The company's research focused on leveraging its expertise in cancer biology and drug development to create innovative treatments for patients with unmet medical needs.
Acquisition by GlaxoSmithKline[edit]
In December 2018, GlaxoSmithKline announced its acquisition of Tesaro, which was completed in January 2019. This acquisition was part of GSK's strategy to strengthen its oncology pipeline and enhance its capabilities in the development of cancer therapies.
